The positive BCBS Association Evidence Street assessment aligns with updated American Society of Clinical Oncology guidelines, which recommend using Prosigna to inform decisions on adjuvant systemic therapy for patients with early-stage breast cancer. The positive Evidence Street assessment is based on clinical and scientific evidence of improved health outcomes.
While Evidence Street does not determine local health plan policies, its review is a step toward health insurance providers in the BCBS affiliate network covering Prosigna.
More articles on payer issues:
Low-cost Texas health plan expands Connecticut network
NC sees 4.4% decrease in ACA health plan enrollments
Insurer mergers can help payers negotiate lower prices with providers, study suggests
